See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: June 27, 2006

Heartburn COPD (Chronic Obstructive Pulmonary Disease) Prostate Cancer

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:


This study will evaluate the safety and efficacy of lansoprazole in preventing frequent heartburn over a full day. Eligible volunteers must be at least 18 who have had heartburn at least two days a week over a one-month period that was not treated, and have taken an over-the-counter medication or antacid.

The research sites are throughout the United States.

More information

Please see


COPD (Chronic Obstructive Pulmonary Disease)

If you have difficulty breathing, you may qualify for a research study testing an investigational drug for people with chronic obstruction pulmonary disorder (COPD). Qualified participants receive study-related medical care at no cost. Compensation for time and travel may be provided.

The research site is in Atlanta, Ga.

More information

Please see


Prostate Cancer

Provenge is an investigational product designed to activate a man's own antigen presenting cells, a type of immune cell, so that they can detect prostate cancer cells and initiate an immune response. Male candidates must be 18 or older who have histologically documented adenocarcinoma of the prostate that has progressed while on hormone therapy and has spread outside the prostate to lymph nodes or bone. Please note that if your cancer has spread to organs including the liver, lung, or brain, you are not eligible for this study.

The research site is in Las Vegas, Nev.

More information

Please see


Copyright 2006 Thomson CenterWatch. All rights reserved.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.